Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by University Hospital, Ghent
Sponsor:
Collaborator:
ConvaTec Inc.
Information provided by (Responsible Party):
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT01107821
First received: April 8, 2010
Last updated: January 29, 2013
Last verified: January 2013

April 8, 2010
January 29, 2013
February 2010
March 2013   (final data collection date for primary outcome measure)
To evaluate safety and efficacy of NPWT with Engenex® [ Time Frame: at least 2 weeks ] [ Designated as safety issue: No ]

Following parameters are assessed:

  • Adverse Events
  • Wound size/volume and clinical aspects (odour, masceration): clinical evaluation, digital photography
  • Degree of pain, measured by a numeric scale and the use of analgesics at each dressing intervention.
  • Control of Bioburden: Rate of critical colonization and/or infection

    •% of patients with clinical infection requiring systemic antimicrobial therapy

  • Monitoring of subject's comfort with the dressing in situ, evaluated by subject.
  • Ease of use and dressing application and dressing removal, evaluated by health care personnel
Performance of NPWT with Engenex® [ Time Frame: at 3 weeks ] [ Designated as safety issue: No ]

Wounds are evaluated clinically at baseline and every dressing change. Specimens for microbiological analysis are taken on admission, if possible, the day prior to inclusion, the day of inclusion and at each dressing change.

Pain, comfort and quality of life measurement are scored prior to therapy start and at each dressing change.

After three weeks plastic surgeons will evaluate whether the wound is ready for surgical closure or not.

Complete list of historical versions of study NCT01107821 on ClinicalTrials.gov Archive Site
To provide instructions for optimal use of Engenex® [ Time Frame: at least 2 weeks ] [ Designated as safety issue: No ]
  • Quality of Life [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
  • therapy cost analysis [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation
Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation

Negative pressure wound therapy (NPWT) has become a powerful tool in wound bed preparation of complex wounds and is routinely used in various disciplines, including general surgery and plastic surgery.

NPWT involves the creation of a controlled subatmospheric pressure in the wound bed. The vacuum is generated by a pump and is distributed over the wound bed by a dressing (mostly a foam or gauze sponge). The therapy has several positive effects on the wound bed, such as improved local blood circulation, stimulation of granulation tissue formation and controlled evacuation of wound exudates. Standard negative pressure applied mostly varies between -120 mmHg and -130 mmHg.A new way of applying NPWT is the Engenex™ system using the Bio-Dome™ Wound Dressing, a specially engineered structure that forms a defined space above the surface of the wound. This space will maintain its size and integrity in the presence of negative pressure and wound fluids and thus effectively imposes strain on the underlying tissue. The material properties of the dressing permit moist wound healing while encouraging efficient removal of exudates. The contact material will not absorb fluid. It has been clinically shown that the Bio-Dome™ Wound Dressing is effective at growing granular tissue in the base of a wound at a safe low negative pressure of -75 mmHg, possibly reducing dressing ingrowth into the wound bed to a minimum.

Our intention is to evaluate NPWT by means of the Engenex™ pump and Bio- Dome™ Wound Dressing in 15 patients. Patients with large soft tissue defects will be examined by a plastic surgeon and if suitable for NPWT they will be treated with the Engenex™ NPWT system.

Before starting NPWT wounds will be evaluated and measured (length, width, depth, volume) if possible. Digital photos will be made and wound swabs will be taken for microbiological examination.Dressing changes will be performed twice weekly, on Monday and Thursday or on Tuesday and Friday. At each dressing change a wound will be re-evaluated and measured.

Other parameters to be noted will be, amongst others: pain, comfort, ease of use,material used, time needed for dressing change, etc.

The NPWT treatment will be carried on for maximum three weeks. During this period plastic surgeons will evaluate whether the wound is ready for surgical closure or not.

If surgical closure after 3 weeks is not yet an option possibility exists that NPWT will be continued.

Every wound will be followed up until complete wound healing after surgical closure.

All patients data will be recorded, secured, evaluated and analysed for both medical parameters and health economic parameters.

Not Provided
Interventional
Phase 4
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Wounds
Device: Engenex™ pump and Bio-Dome™ Wound Dressing
Engenex™ pump and Bio-Dome™ Wound Dressing is used.
Experimental: Engenex™-pump
Negative Pressure Wound Therapy with the Engenex™-pump and Bio-Dome™ Dressing
Intervention: Device: Engenex™ pump and Bio-Dome™ Wound Dressing
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
15
March 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

Wounds will be assessed by plastic surgeons to evaluate the indication for wound bed preparation. If suitable for NPWT, they will be treated with Engenex® NPWT-system.

  • Suitable wounds include:

    • Pressure sores grade III and IV
    • Traumatic wounds with considerable soft tissue loss
    • Wounds after necrotizing fasciitis
    • Abdominal wounds

Exclusion Criteria:

  • Impossibility to adhere the polyurethane film to healthy surrounding skin
  • Malignancy in the wound
  • Untreated osteomyelitis
  • Non-enteric and unexplored fistula
  • Undebrided wounds with necrotic tissue
  • Exposed organs and blood vessels (Always protect vessels, organs, and nerves by covering them with natural tissues or several layers of fine-meshed, non-adherent synthetic material that form a complete barrier.)
  • Increased risk of bleeding
  • Patient has one or more medical condition(s), diabetes, including renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the investigator would make the patient inappropriate for this trial
  • The plastic surgeon decides that NPWT therapy should be stopped for other reasons than failure of the NPWT therapy
  • Less than two weeks of NPWT
Both
up to 80 Years
No
Contact: Henk Hoeksema, PT henk.hoeksema@ugent.be
Contact: Jozef Verbelen, RN, MN jozef.verbelen@ugent.be
Belgium
 
NCT01107821
2009/597
No
University Hospital, Ghent
University Hospital, Ghent
ConvaTec Inc.
Principal Investigator: Stan Monstrey, MD, PhD University Hospital, Ghent
University Hospital, Ghent
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP